Market Cap 161.30B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 9.37
Forward PE 9.60
Profit Margin 12.42%
Debt to Equity Ratio 0.74
Volume 31,174,400
Avg Vol 44,044,414
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 72%
Beta 0.34
Analysts Sell
Price Target $28.60

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
BadBlake
BadBlake Aug. 28 at 1:50 PM
$CVX $MSFT $PFE $PSKY $UNH this is what the system has become, sounds more like soviet than American. TERM LIMITS and REMOVE the MONEY from politics. only way we get honest actors making honest decisions…
0 · Reply
Outcomes
Outcomes Aug. 28 at 1:28 PM
$MRNA $MRK $PFE $JNJ .....how could I forget to copy this group!?
0 · Reply
green_going_up
green_going_up Aug. 28 at 1:17 PM
$BNTX halted a trial; firm has not been able to really gain traction using its mRNA platform outside of COVID; originally, I was surprised that $PFE - it's partner in COVID - didn't acquire BNTX and decided to develop its own mRNA platform. Pfizer clearly viewed that BNTX's mRNA platform - while useful in COVID - was not as robust of an mRNA platform as it could develop on its own. That has since been shown in cancer trials to date; BNTX's mRNA platform clearly lags that of $MRNA
0 · Reply
sam92
sam92 Aug. 28 at 12:27 PM
$PFE Pfizer-backed Priovant wins FDA approval for lead asset
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 28 at 12:24 PM
$ABBV $AZN $JNJ $PFE $SLS All the Repositioners, traders will be left on the sidelines when the T1 halt hits. Shorts are burying themselves deeper and deeper before liquidation 🔥 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 28 at 12:13 PM
$SLS $JNJ $PFE $ABBV $AZN Every passing day starting to look like Data+Deal coming in Consecutive order. ✌️🙏❤️‍🩹
0 · Reply
DonCorleone77
DonCorleone77 Aug. 28 at 11:17 AM
$PSKY $CVX $PFE $UNH $MSFT U.S. companies work to gain favor with Democrats, WSJ reports THIS IS THE PROBLEM WITH THE CURRENT CRONY CAPITALIST SYSTEM IN THE UNITED STATES. THESE COMPANIES ALL FLIPPED TO THE CURRENT ADMINISTRATION, DONATED MONEY AND PLAYED THE GAME TO GAIN FAVOR WITH THE TRUMP. NOW, GIVEN IT LOOKS LIKE THE DEMOCRATS WILL LIKELY GAIN CONTROL OF CONGRESS AFTER THE MID-TERMS, THEY ARE TRYING TO GAIN FAVOR WITH THE DEMOCRATS. IMHO, A SOCIETY CAN'T SURVIVE WHEN THE TRUE STRING PULLERS (THE CORPORATIONS WITH THE MONEY) PLAY THIS GAME AND NO ONE STANDS FOR ANYTHING OTHER THAN GAINING FAVOR WITH WHOEVER IS VOTED IN AT ANY GIVEN TIME. Some U.S. companies with close ties to President Trump are trying to gain favor with Democrats in case they become targets if Republicans lose control of the House, Annie Linskey and Emily Glazer of The Wall Street Journal reports. Big tech companies are preparing for congressional and criminal investigators, some advisers, lobbyists, and board members told the Journal. Meta (META) and others are writing big checks for Democrats; Paramount (PSKY), Kalshi, and others are hiring former Democratic aides to bolster government relations; and Meta and Palantir (PLTR) are among the companies concerned about future requests for information, congressional hearings, and subpoenas, sources told the Journal. Additionally, executives from Amazon (AMZN), Chevron (CVX), Pfizer (PFE), UnitedHealth (UNH) and others attended a summer seminar hosted by the U.S. Chamber of Commerce that focused on "managing potential congressional oversight and investigations," according to documents reviewed by the Journal.
1 · Reply
notreload_ai
notreload_ai Aug. 28 at 11:14 AM
Newly approved Lisraya could become a blockbuster. J.P. Morgan calls dermatomyositis highly attractive and sees $2B+ U.S. peak sales. $ROIV, $PFE https://notreload.xyz/xy/fda-approves-roiv-pfe-lisraya-first-oral-therapy-for-dermatomyositis/
0 · Reply
MrsFroggy
MrsFroggy Aug. 28 at 10:58 AM
0 · Reply
Outcomes
Outcomes Aug. 28 at 10:42 AM
$IBRX $MRNA $MRK $PFE $JNJ https://x.com/Berlinergy/status/2027713838502547676?s=20
0 · Reply
Latest News on PFE
Pfizer Stock (PFE) Is a Buy despite Declining Revenue

2026-08-24T12:18:00.000Z - 4 days ago

Pfizer Stock (PFE) Is a Buy despite Declining Revenue


Pfizer, Valneva announce EMA validation for PF-07307405 MAA

2026-08-16T13:55:21.000Z - 12 days ago

Pfizer, Valneva announce EMA validation for PF-07307405 MAA

VALN


Pfizer (PFE) CEO Buys $1 Million of Company Stock

2026-08-14T18:45:04.000Z - 13 days ago

Pfizer (PFE) CEO Buys $1 Million of Company Stock


Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 23 days ago

Pfizer Earnings Call Transcript: Q2 2026


Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 23 days ago

Pfizer Earnings release: Q2 2026


Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 23 days ago

Pfizer Slides: Q2 2026


Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 23 days ago

Pfizer Quarterly report: Q2 2026


Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 24 days ago

Pfizer Post Loss on Higher Revenue


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 7 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 2 months ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 2 months ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 2 months ago

Pfizer's experimental drug misses main goal of lung cancer trial


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update


Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 3 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026


BadBlake
BadBlake Aug. 28 at 1:50 PM
$CVX $MSFT $PFE $PSKY $UNH this is what the system has become, sounds more like soviet than American. TERM LIMITS and REMOVE the MONEY from politics. only way we get honest actors making honest decisions…
0 · Reply
Outcomes
Outcomes Aug. 28 at 1:28 PM
$MRNA $MRK $PFE $JNJ .....how could I forget to copy this group!?
0 · Reply
green_going_up
green_going_up Aug. 28 at 1:17 PM
$BNTX halted a trial; firm has not been able to really gain traction using its mRNA platform outside of COVID; originally, I was surprised that $PFE - it's partner in COVID - didn't acquire BNTX and decided to develop its own mRNA platform. Pfizer clearly viewed that BNTX's mRNA platform - while useful in COVID - was not as robust of an mRNA platform as it could develop on its own. That has since been shown in cancer trials to date; BNTX's mRNA platform clearly lags that of $MRNA
0 · Reply
sam92
sam92 Aug. 28 at 12:27 PM
$PFE Pfizer-backed Priovant wins FDA approval for lead asset
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 28 at 12:24 PM
$ABBV $AZN $JNJ $PFE $SLS All the Repositioners, traders will be left on the sidelines when the T1 halt hits. Shorts are burying themselves deeper and deeper before liquidation 🔥 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 28 at 12:13 PM
$SLS $JNJ $PFE $ABBV $AZN Every passing day starting to look like Data+Deal coming in Consecutive order. ✌️🙏❤️‍🩹
0 · Reply
DonCorleone77
DonCorleone77 Aug. 28 at 11:17 AM
$PSKY $CVX $PFE $UNH $MSFT U.S. companies work to gain favor with Democrats, WSJ reports THIS IS THE PROBLEM WITH THE CURRENT CRONY CAPITALIST SYSTEM IN THE UNITED STATES. THESE COMPANIES ALL FLIPPED TO THE CURRENT ADMINISTRATION, DONATED MONEY AND PLAYED THE GAME TO GAIN FAVOR WITH THE TRUMP. NOW, GIVEN IT LOOKS LIKE THE DEMOCRATS WILL LIKELY GAIN CONTROL OF CONGRESS AFTER THE MID-TERMS, THEY ARE TRYING TO GAIN FAVOR WITH THE DEMOCRATS. IMHO, A SOCIETY CAN'T SURVIVE WHEN THE TRUE STRING PULLERS (THE CORPORATIONS WITH THE MONEY) PLAY THIS GAME AND NO ONE STANDS FOR ANYTHING OTHER THAN GAINING FAVOR WITH WHOEVER IS VOTED IN AT ANY GIVEN TIME. Some U.S. companies with close ties to President Trump are trying to gain favor with Democrats in case they become targets if Republicans lose control of the House, Annie Linskey and Emily Glazer of The Wall Street Journal reports. Big tech companies are preparing for congressional and criminal investigators, some advisers, lobbyists, and board members told the Journal. Meta (META) and others are writing big checks for Democrats; Paramount (PSKY), Kalshi, and others are hiring former Democratic aides to bolster government relations; and Meta and Palantir (PLTR) are among the companies concerned about future requests for information, congressional hearings, and subpoenas, sources told the Journal. Additionally, executives from Amazon (AMZN), Chevron (CVX), Pfizer (PFE), UnitedHealth (UNH) and others attended a summer seminar hosted by the U.S. Chamber of Commerce that focused on "managing potential congressional oversight and investigations," according to documents reviewed by the Journal.
1 · Reply
notreload_ai
notreload_ai Aug. 28 at 11:14 AM
Newly approved Lisraya could become a blockbuster. J.P. Morgan calls dermatomyositis highly attractive and sees $2B+ U.S. peak sales. $ROIV, $PFE https://notreload.xyz/xy/fda-approves-roiv-pfe-lisraya-first-oral-therapy-for-dermatomyositis/
0 · Reply
MrsFroggy
MrsFroggy Aug. 28 at 10:58 AM
0 · Reply
Outcomes
Outcomes Aug. 28 at 10:42 AM
$IBRX $MRNA $MRK $PFE $JNJ https://x.com/Berlinergy/status/2027713838502547676?s=20
0 · Reply
Outcomes
Outcomes Aug. 28 at 10:41 AM
$IBRX $MRNA $MRK $PFE $JNJ .......mRNA BAD. 'There is not one Oncologist in the United States or Canada that has the guts to say COVID-19 Vaccines cause cancer. Not one.' except: Dr. Pat.....'Turbo-Cancers' PSS knows. https://x.com/blueshot007/status/2089517782639821263?s=20
1 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 28 at 12:55 AM
$BHVN $PFE hmmm!! biohaven pfe Pfizer Inc. completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd. on October 3, 2022, for approximately $11.6 billion in cash. [1, 2] Deal Terms Cash Payment: Biohaven shareholders received $148.50 per share in cash. New Biohaven Spin-off: Shareholders also received 0.5 of a share in a new separate company ("New Biohaven") that kept the non-CGRP pipeline compounds. Total Value: The cash portion of the transaction was valued at $11.6 billion. [1, 2] Key Products & Assets NURTEC® ODT (rimegepant): An innovative pill approved to treat and prevent migraines in adults. VYDURA®: The European Union trade name for rimegepant. CGRP Portfolio: A collection of calcitonin gene-related peptide receptor antagonists designed for neurological diseases. [1]
0 · Reply
JBS_84
JBS_84 Aug. 27 at 11:52 PM
$PFE Positive articles so institutions can get short at a high price. They've no doubt took their positions by now, and you will begin seeing the price pullback followed by negative articles. I've said it before when everyone's saying it's going to 50, You sell when everyone's saying it's going to 20 buy. Simple.
0 · Reply
KilroyPicks
KilroyPicks Aug. 27 at 9:37 PM
$MIST - Rome wasn't built in a day. This drug is a specialty drug with a specific and relatively small patient base less than 1% of the US population. Also, this is Milestone's first drug so they are building relationships from scratch from doctors to the formulary channels. This will take a little longer to build than a drug from say Pfizer & $PFE or J&J $JNJ or Bristol-Myer Squib $BMY , those companies already have the relationships in place.
2 · Reply
focafoca99
focafoca99 Aug. 27 at 8:55 PM
$PFE got FDA approval for its XFG-adapted COVID-19 vaccine for seniors and high-risk adults. https://www.rapidticker.com/news/pfe-pfizer-and-biontech-receive-us-e396bc
0 · Reply
Outcomes
Outcomes Aug. 27 at 8:55 PM
$IBRX $MRNA $PFE $JNJ ......'why did I choose this career path? I am seeing so much carnage. I beg you. I am seeing so much autoimmunity developing. I've seen 4 men trying to conceive, not one single functioning sperm.' mRNA BAD. 'It is beyond all reasonable doubt' mRNA causes 'Turbo-cancers. And now, mRNA for cancer treatment. THE ULTIMATE HYPOCRISY. PSS KNOWS. https://x.com/ImBreckWorsham/status/2092973899935858784?s=20 SAVE THE CHILDREN. 🙏
5 · Reply
goguryo2000
goguryo2000 Aug. 27 at 8:35 PM
$PFE Recent Pipeline and Regulatory Updates Lyme Disease Vaccine: The European Medicines Agency (EMA) validated the Marketing Authorization Application for Pfizer and Valneva's joint Lyme disease vaccine candidate. Prostate Cancer Review: The FDA granted Priority Review for Pfizer's Talzenna combined with Xtandi to treat metastatic prostate cancer. Bladder Cancer Approval: The FDA approved Padcev plus Keytruda for muscle-invasive bladder cancer. Vitiligo Results: Pfizer announced positive Phase 3 topline results for Litfulo in patients suffering from nonsegmental vitiligo. Financial and Market Position Guidance: Management raised the 2026 revenue guidance midpoint by $500 million following steady non-COVID revenue recovery. Dividends: The company declared its third-quarter 2026 dividend while balancing cost-cutting initiatives to offset declining pandemic-era product sales.
0 · Reply
goguryo2000
goguryo2000 Aug. 27 at 7:50 PM
$PFE Happy with 28. Looking forward for 30. Happy trading.
1 · Reply
NorthOfSouth
NorthOfSouth Aug. 27 at 6:55 PM
$PFE This super f'd up market really started April 2025 when a certain individual made false claims about tariffs and crashed the markets...then repealed them and markets shot up...who loaded up at that time? Been pumped (AI) incessantly since then...Q: is when (after the major short positions have been established) will the plug be pulled? I know that I want a chair when the music stops...
2 · Reply
FlowAnomaly
FlowAnomaly Aug. 27 at 4:55 PM
$RVMD calls printing $MRNA $PFE $VSTM
0 · Reply
Loudermilk64
Loudermilk64 Aug. 27 at 4:05 PM
$PFE Pulling back up higher on the 1 week.
0 · Reply
StUngarjr
StUngarjr Aug. 27 at 4:04 PM
$PFE l’m writing this from the hospital. I just woke up after a 22 year coma. I see the stocks at 28 which it was when I went in to the coma. Question, how many times have we split? I can’t see my brokerage account yet, but must’ve split like 10 times since? So I have 10,000 shares not 1000?
0 · Reply